Celecoxib-d7
Based on 1 Customer Validation
Celecoxib-d7 is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.58%
- No. CAS: 544686-21-7
- Fòrmula: C17H7D7F3N3O2S
- Peso molecular:388.42
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
No. CAS 544686-21-7
-
Unlabeled Cas 169590-42-5
-
Appearance Solid
-
Peso molecular 388.42
-
Fòrmula C17H7D7F3N3O2S
-
Color Off-white to gray
-
SMILES
NS(C1=CC=C(C=C1)N2C(C3=C(C([2H])=C(C([2H])=C3[2H])C([2H])([2H])[2H])[2H])=CC(C(F)(F)F)=N2)(=O)=O
-
Synonyms
SC 58635-d7
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : ≥ 76 mg/mL (195.66 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : ≥ 33 mg/mL (84.96 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (281 KB)
-
SDS (760 KB)
- English - EN (760 KB)
- Français - FR (760 KB)
- Deutsch - DE (760 KB)
- Norwegian - NO (760 KB)
- Español - ES (760 KB)
- Swedish - SV (760 KB)
- Italian - IT (760 KB)
- Korean - KR (760 KB)
- Portuguese - PT (760 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Penning TD, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 [Content Brief]
[3]. Liu DB, et al. Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation. Acta Pharmacol Sin. 2012 May;33(5):682-90. [Content Brief]
[4]. Suri A, et al. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016 Apr 8. [Content Brief]
[5]. Hou XL, et al. Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone. Neural Regen Res. 2015 Nov;10(11):1836-40. [Content Brief]
[6]. Liu C, et al. Celecoxib alleviates nonalcoholic fatty liver disease by restoring autophagic flux. Sci Rep. 2018 Mar 7;8(1):4108. [Content Brief]
[7]. Pobbati AV, et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020 Feb 18;10(8):3622-3635. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.5745 mL | 12.8727 mL | 25.7453 mL | 64.3633 mL |
| 5 mM | 0.5149 mL | 2.5745 mL | 5.1491 mL | 12.8727 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5745 mL | 6.4363 mL | |
| 15 mM | 0.1716 mL | 0.8582 mL | 1.7164 mL | 4.2909 mL | |
| 20 mM | 0.1287 mL | 0.6436 mL | 1.2873 mL | 3.2182 mL | |
| 25 mM | 0.1030 mL | 0.5149 mL | 1.0298 mL | 2.5745 mL | |
| 30 mM | 0.0858 mL | 0.4291 mL | 0.8582 mL | 2.1454 mL | |
| 40 mM | 0.0644 mL | 0.3218 mL | 0.6436 mL | 1.6091 mL | |
| 50 mM | 0.0515 mL | 0.2575 mL | 0.5149 mL | 1.2873 mL | |
| 60 mM | 0.0429 mL | 0.2145 mL | 0.4291 mL | 1.0727 mL | |
| 80 mM | 0.0322 mL | 0.1609 mL | 0.3218 mL | 0.8045 mL | |
| DMSO | 100 mM | 0.0257 mL | 0.1287 mL | 0.2575 mL | 0.6436 mL |
Celecoxib-d7 Related Classifications
HY-14398S Related Classifications
Powered by Bioz